BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35773357)

  • 1. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    AbdelRazek M; Abolyosr A; Mhammed O; Fathi A; Talaat M; Hassan A
    World J Urol; 2022 Aug; 40(8):2063-2070. PubMed ID: 35773357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating Lower Urinary Tract Symptoms Caused by Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Meta-Analysis.
    Liu J; Zhou W; Zhang P; Zhang W; Chang C; Fu G
    Urol Int; 2024; 108(2):89-99. PubMed ID: 38081154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Yoshida M; Origasa H; Seki N
    Low Urin Tract Symptoms; 2017 Sep; 9(3):176-186. PubMed ID: 28439987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
    Singh I; Tk A; Gupta S
    Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates.
    Buono R; Briganti A; Freschi M; Villa L; La Croce G; Moschini M; Benigni F; Castiglione F; Montorsi F; Hedlund P
    Eur J Pharmacol; 2014 Dec; 744():42-51. PubMed ID: 25261033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
    Amano T; Earle C; Imao T; Matsumoto Y; Kishikage T
    Aging Male; 2018 Mar; 21(1):77-82. PubMed ID: 28830281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.
    Sebastianelli A; Spatafora P; Frizzi J; Saleh O; De Nunzio C; Tubaro A; Vignozzi L; Maggi M; Serni S; McVary KT; Kaplan SA; Gravas S; Chapple C; Gacci M
    Eur Urol Focus; 2021 Mar; 7(2):432-439. PubMed ID: 31606473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication.
    Madani AH; Afsharimoghaddam A; Roushani A; Farzan A; Asadollahzade A; Shakiba M
    Int Braz J Urol; 2012; 38(1):33-9. PubMed ID: 22397784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.